Price movement over the last 24 hours
Align Technology, Inc. vs Axogen Inc — how do they compare? Align Technology, Inc. trades at $173.86 (market cap $13.27B), while Axogen Inc trades at $42.61 (market cap $2.37B). The key difference: Align Technology, Inc. is far larger — about 5.6× Axogen Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Align Technology, Inc. nearer its low. Which is the better fit depends on your goals.
| ALGN | AXGN | |
|---|---|---|
Market Cap | $13.27B | $2.37B |
Sector | Health | Technology |
52-Week High | $207.19 | $46.19 |
52-Week Low | $124.88 | $11.28 |
Enterprise Value | $12.32B | $2.29B |
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $185.22, up 0.38% today, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Revenue remains stable around $4.0B, supported by a 67.57% gross margin and positive cash flow trends. Recent news highlights global expansion and product innovation, including a new manufacturing facility in India.
Outlook is positive with a $220.75 consensus price target, though risks include regulatory scrutiny from the European Commission and competitive pressures. The stock's valuation at a P/E of 31.65 reflects growth expectations, but investors should monitor execution on international growth and demand stability in North America.
AXGN trades at $45.97, up 0.17% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 earnings of $0.07 per share, missing estimates, yet maintains a strong gross margin of 75.01%. Recent news highlights a bullish rebound and raised 2026 guidance, with 84% of analysts rating it a Buy. Support is at $44, with resistance at $47.
Outlook is cautiously optimistic due to strong analyst support and recent institutional interest, but risks include consecutive earnings misses and negative net income margins. The consensus price target of $47.60 suggests modest upside, though execution on guidance and reimbursement wins are critical for sustained growth.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →